Risk of Death Following Admission to A UK Hospital with Diabetic Ketoacidosis
Gibb FW, Teoh WL, Graham J, et al. Diabetologia 2016;59(10):2082-7 http://link.springer.com/article/10.1007/s00125-016-4034-0?wt_mc=alerts.TOCjournals
Leggi
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus) – 4 Study
Franchi F, Rollini F, Aggarwal N,et al. Circulation 2016;134:780-92 http://circ.ahajournals.org/content/134/11/780.abstract
Leggi
Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated with Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients) (Res
Mangiacapra F, Panaioli E, Colaiori I, et al. Circulation 2016;134:835-7 http://circ.ahajournals.org/content/134/11/835.extract
Leggi
Choices for Potent Platelet Inhibition in Patients with Diabetes Mellitus (Editorial)
Storey RF, Parker WAE Circulation 2016;134:793-6 http://circ.ahajournals.org/content/134/11/793.extract
Leggi
Insulin Infusion Set Use: European Perspectives and Recommendations
Deiss D, Adolfsson P, Alkemade-van Zomeren M, et al. Diabetes Technol Ther 2016;18(9):517-24 http://online.liebertpub.com/doi/abs/10.1089/dia.2016.07281.sf#utm_source=ETOC&utm_medium=email&utm_campaign=dia
Leggi
Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, Phase 3, Randomised Controll
Frías JP, Guja C, Hardy E, Ahmed A, et al. Lancet Diabetes Endocrinol. Pub. online September 2016 http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30267-4/fulltext
Leggi
GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Couple at Last?
Nauck MA, Meier JJ Lancet Diabetes Endocrinol. Pub. online September 2016 http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30263-7/fulltext
Leggi
Association Between Socioeconomic Status and Mortality, Cardiovascular Disease, and Cancer in Patients with Type 2 Diabetes
Rawshani A, Svensson AM, Zethelius B, et al. JAMA Intern Med 2016;176(8):1146-1154 http://archinte.jamanetwork.com/article.aspx?articleid=2530287
Leggi
Quantifying the Association Between Physical Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta?Analysis
Wahid A, Manek N, Nichols M, et al. J Am Heart Assoc. Pub. online September 14, 2016 http://jaha.ahajournals.org/content/5/9/e002495.abstract
Leggi
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, et al. N Engl J Med 2016; September 16 http://www.nejm.org/doi/full/10.1056/NEJMoa1607141
Leggi